MX360189B - Terapia de combinacion para el tratamiento de glioblastoma. - Google Patents

Terapia de combinacion para el tratamiento de glioblastoma.

Info

Publication number
MX360189B
MX360189B MX2015001627A MX2015001627A MX360189B MX 360189 B MX360189 B MX 360189B MX 2015001627 A MX2015001627 A MX 2015001627A MX 2015001627 A MX2015001627 A MX 2015001627A MX 360189 B MX360189 B MX 360189B
Authority
MX
Mexico
Prior art keywords
glioblastoma
treatment
combination therapy
patient
therapy
Prior art date
Application number
MX2015001627A
Other languages
English (en)
Other versions
MX2015001627A (es
Inventor
Asha Das
Ana Maria Abajo Guijarro
Lauren Abrey
Josep Garcia
Magalie Hilton
Yannick Kerloeguen
Nicola Moore
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48985869&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX360189(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2015001627A publication Critical patent/MX2015001627A/es
Publication of MX360189B publication Critical patent/MX360189B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oncology (AREA)

Abstract

La presente invención se refiere a métodos para tratar a un paciente diagnosticado con glioblastoma, el cual comprende administrar al paciente una terapia que consiste de una cantidad efectiva de un anticuerpo anti-VEGF y un producto quimioterapéutico.
MX2015001627A 2012-08-07 2013-08-06 Terapia de combinacion para el tratamiento de glioblastoma. MX360189B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261680672P 2012-08-07 2012-08-07
US201261714438P 2012-10-16 2012-10-16
US201361760763P 2013-02-05 2013-02-05
PCT/US2013/053841 WO2014025813A1 (en) 2012-08-07 2013-08-06 Combination therapy for the treatment of glioblastoma

Publications (2)

Publication Number Publication Date
MX2015001627A MX2015001627A (es) 2015-06-23
MX360189B true MX360189B (es) 2018-10-24

Family

ID=48985869

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015001627A MX360189B (es) 2012-08-07 2013-08-06 Terapia de combinacion para el tratamiento de glioblastoma.

Country Status (15)

Country Link
US (2) US20150148585A1 (es)
EP (2) EP3446709A1 (es)
JP (4) JP6464085B2 (es)
KR (3) KR20180011356A (es)
CN (1) CN104507498A (es)
AU (3) AU2013299724A1 (es)
BR (1) BR112015002681A2 (es)
CA (1) CA2880767A1 (es)
HK (1) HK1204993A1 (es)
IL (2) IL237028B (es)
MX (1) MX360189B (es)
RU (1) RU2015104001A (es)
SG (1) SG11201500903XA (es)
WO (1) WO2014025813A1 (es)
ZA (1) ZA201500811B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230070054A (ko) 2013-03-15 2023-05-19 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) * 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
MX2016010505A (es) * 2014-02-14 2017-04-13 S Chi Andrew Metodos mejorados para el tratamiento de canceres vascularizantes.
US10780182B2 (en) 2014-04-25 2020-09-22 The Trustees Of The University Of Pennsylvania Methods and compositions for treating metastatic breast cancer and other cancers in the brain
US20170058025A1 (en) * 2014-05-07 2017-03-02 Medlmmune, Llc Methods of using anti-ang2 antibodies
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US20160009805A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Anti-pd-l1 antibodies and diagnostic uses thereof
EP3169801A1 (en) * 2014-07-14 2017-05-24 F. Hoffmann-La Roche AG Diagnostic methods and compositions for treatment of glioblastoma
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
JP7263665B2 (ja) 2017-06-12 2023-04-25 レ ラボラトワール セルヴィエ 併用療法を用いて脳腫瘍を処置する方法
WO2018231796A1 (en) * 2017-06-12 2018-12-20 Agios Pharmaceuticals, Inc. Methods of treating brain tumors using combination therapy
JP2022553640A (ja) 2019-10-10 2022-12-26 コディアック サイエンシーズ インコーポレイテッド 眼障害を処置する方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
HU221343B1 (en) 1992-10-28 2002-09-28 Genentech Inc Use of anti-vegf antibodies for the treatment of cancer
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
ES2273415T3 (es) 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
DE69842174D1 (de) 1997-04-07 2011-04-21 Genentech Inc Verfahren zur Herstellung humanisierter Antikörper durch randomisierte Mutagenese
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US20030180714A1 (en) 1999-12-15 2003-09-25 Genentech, Inc. Shotgun scanning
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7041870B2 (en) 2000-11-30 2006-05-09 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
US20050079574A1 (en) 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
CA2526085A1 (en) 2003-05-30 2005-01-06 Genentech, Inc. Treatment with anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
AU2005230848B9 (en) 2004-03-31 2011-06-02 Genentech, Inc. Humanized anti-TGF-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
US20120052080A1 (en) * 2004-09-21 2012-03-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
CA2651567A1 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
MA33323B1 (fr) * 2009-04-20 2012-06-01 Genentech Inc Thérapie adjuvante de cancer
CA2787952C (en) * 2010-02-23 2016-07-26 Genentech, Inc. Anti-angiogenesis therapy for the treatment of ovarian cancer
US20120114638A1 (en) * 2010-11-08 2012-05-10 John Boylan Combination therapy

Also Published As

Publication number Publication date
EP2882454A1 (en) 2015-06-17
RU2015104001A (ru) 2016-09-27
JP2018008946A (ja) 2018-01-18
CA2880767A1 (en) 2014-02-13
EP3446709A1 (en) 2019-02-27
KR20150038593A (ko) 2015-04-08
SG11201500903XA (en) 2015-03-30
WO2014025813A1 (en) 2014-02-13
JP2015525798A (ja) 2015-09-07
MX2015001627A (es) 2015-06-23
JP2021138704A (ja) 2021-09-16
IL263661A (en) 2019-01-31
AU2013299724A1 (en) 2015-02-26
JP6464085B2 (ja) 2019-02-06
IL237028B (en) 2019-03-31
ZA201500811B (en) 2016-10-26
HK1204993A1 (en) 2015-12-11
KR20180011356A (ko) 2018-01-31
EP2882454B1 (en) 2018-10-10
BR112015002681A2 (pt) 2018-08-28
JP2019147812A (ja) 2019-09-05
AU2016244262A1 (en) 2016-11-03
KR20190088571A (ko) 2019-07-26
CN104507498A (zh) 2015-04-08
US20200086139A1 (en) 2020-03-19
US20150148585A1 (en) 2015-05-28
AU2018253461A1 (en) 2018-11-15
AU2016244262B2 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
MX2016002645A (es) Tratamiento combinado para tratar el glioblastoma.
MX360189B (es) Terapia de combinacion para el tratamiento de glioblastoma.
HK1247567A1 (zh) 用於治療癌症的涉及針對密蛋白18.2之抗體的聯合治療
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
MX2020011783A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2015002947A (es) Terapia de combinacion de un anticuerpo ant-cd20 tipo ii con un inhibidor blc-2 selectivo.
DK3791896T3 (da) Kombinationsterapi med antistoffer mod claudin 18.2 til cancerbehandling
PH12014501543A1 (en) Combination therapy for the treatment of ovarian cancer
PH12015500246A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
SI2852408T1 (sl) Kombinacijska terapija, ki vključuje protitelesa proti claudin 18.2 za zdravljenje raka
MX354725B (es) Metodo de tratamiento de una enfermedad proliferativa.
WO2012106473A8 (en) Dosing for treatment with anti-egfl7 antibodies
NZ745950A (en) Methods and compositions for treating multiple sclerosis and related disorders

Legal Events

Date Code Title Description
FG Grant or registration